SBS Law Investigates Tenax Therapeutics Investor Claims

Tenax Therapeutics shares fell by almost 90% after the company said its Phase 3 LEVEL trial of TNX-103 failed to meet its primary and secondary endpoints. Schall, Brown & Schwartz LLP says it is investigating whether Tenax made false or misleading statements or withheld information relevant to investors.

November 9, 2026, 11:34 AM Bio & News 334 0

Photo: Bio & News

The Los Angeles-based shareholder rights firm announced the investigation on Nov. 9, 2026. It concerns potential securities-law violations involving Tenax Therapeutics, Inc., which trades on the Nasdaq under the ticker TENX.

Investors who suffered losses can contact attorneys Brian Schall or David Schwartz at 310-301-3335 to discuss their rights free of charge. The firm lists its address as 2049 Century Park East, Suite 2460, Los Angeles, CA 90067. It also provides contact details at www.schallfirm.com and david@schallfirm.com.

When reusing this material a link to Money Talk is required.